Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RNF4 | P78317 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6732824 | 0.82 | HTT (0.48) | MAPK14LMNASMN1; SMN2STAT3TSHR | |
| SCHEMBL7420781 | 0.82 | CYP3A4 (0.44) | MAPK14LMNASMN1; SMN2STAT3TSHR | |
| SCHEMBL6736436 | 0.80 | MAPK14 (0.49) | MAPK14SMN1; SMN2MEN1KMT2ARNF4 | |
| SCHEMBL6733763 | 0.77 | MAPK14 (0.51) | MAPK14SMN1; SMN2RNF4ALDH1A1TRPM8 | |
| SCHEMBL6738576 | 0.75 | MAPK14 (0.52) | MAPK14SMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL6736102 | 0.74 | MLYCD (0.49) | MAPK14SMN1; SMN2TSHRRNF4ALDH1A1 | |
| SCHEMBL3988369 | 0.71 | HPGD (0.49) | SMN1; SMN2MEN1KMT2AALDH1A1POLB | |
| SCHEMBL6727502 | 0.70 | LMNA (0.53) | MAPK14LMNASMN1; SMN2STAT3RNF4 | |
| SCHEMBL5881049 | 0.69 | FFAR1 (0.62) | LMNAALDH1A1MAPT | |
| SCHEMBL6858765 | 0.69 | HPGD (0.50) | LMNASMN1; SMN2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | MAPK14 3282/4885LMNA 4863/4885SMN1; SMN2 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.